(E)-1-ethoxy-4-methylpent-2-ene

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-1-ethoxy-4-methylpent-2-ene
• 化学式: C₈H₁₆O
• 分子量: 128.21
• InChiKey: XLTXOKDODGBUDF-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：McCauley John A.

  公开号：US20110002884A1

  公开（公告）日：2011-01-06

  A class of macrocyclic compounds of formula (I), wherein R 1 , R 3 , R 4 , R a , R b , A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.

  提供一类具有化学式（I）的大环化合物，其中R1、R3、R4、Ra、Rb、A、B、Z、M、W和n在此定义，这些化合物可用作病毒蛋白酶抑制剂，特别是乙型肝炎病毒（HCV）NS3蛋白酶的抑制剂。还提供了合成和使用这种大环化合物用于治疗或预防HCV感染的过程。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20100260715A1

  公开（公告）日：2010-10-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20120076756A1

  公开（公告）日：2012-03-29

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8785487B2
  申请人：——

  公开号：US8785487B2

  公开（公告）日：2014-07-22
• US8933110B2
  申请人：——

  公开号：US8933110B2

  公开（公告）日：2015-01-13